IPCI - IntelliPharmaCeutics International Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2199
+0.0035 (+1.62%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2164
Open0.2200
Bid0.2060 x 1000
Ask0.2390 x 1100
Day's Range0.2151 - 0.2294
52 Week Range0.2000 - 10.5000
Volume668,978
Avg. Volume1,114,328
Market Cap2.173M
Beta (3Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-3.2570
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.50
Trade prices are not sourced from all markets
  • ACCESSWIRE10 days ago

    NASDAQ Schedules Hearing to Consider Intellipharmaceutics’ (TM) Continued Listing

    TORONTO, ON / ACCESSWIRE / December 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received written notification (the ''Notification'')from The Nasdaq Stock Market LLC ('NASDAQ'') notifying the Company that a hearing with a Nasdaq Hearings Panel (the ''Panel'')has been scheduled for January 10, 2019. As previously reported, the minimum bid price per share for the Company's common shares was below $1.00 for a period of 30 consecutive business days and, as a result, the Company is currently not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

  • Benzinga17 days ago

    The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 27) ...

  • ACCESSWIRE17 days ago

    Today’s Research Reports on Stocks to Watch: IntelliPharmaCeutics International and Bristol-Myers Squibb

    NEW YORK, NY / ACCESSWIRE / November 28, 2018 / It was a big sell off for IntelliPharmaCeutics on Tuesday despite encouraging FDA news. Shares of Bristol-Myers Squibb Company was also in the red after ...

  • ACCESSWIRE17 days ago

    Intellipharmaceutics Announces FDA Final Approval of Generic Effexor® XR

    TORONTO, ON / ACCESSWIRE / November 27, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for venlafaxine hydrochloride extended-release capsules in the 37.5, 75, and 150 mg strengths. The approved product is a generic equivalent of the branded product Effexor® XR sold in the U.S. by Wyeth Pharmaceuticals, LLC.

  • ACCESSWIRE18 days ago

    Intellipharmaceutics Submits Investigational New Drug Application to the U.S. FDA for IPCI006 (oxycodone hydrochloride immediate release) Tablets Incorporating its Abuse Deterrent and Overdose Resistant Technology

    TORONTO, ON / ACCESSWIRE / November 27, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has submitted an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for its oxycodone hydrochloride immediate release ("IPCI006") tablets in the 5 mg, 10 mg, 15 mg, 20 mg and 30 mg strengths. Oxycodone hydrochloride is indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. This novel drug formulation incorporates the Company's Paradoxical OverDose Resistance Activating System ("PODRAS™") delivery technology and its novel Point Of Divergence Drug Delivery System ("nPODDDS™") technology.

  • ACCESSWIRE18 days ago

    Intellipharmaceutics Announces Receipt of Nasdaq Notice

    TORONTO, ON / ACCESSWIRE / November 26, 2018 / Intellipharmaceutics International Inc. (Nasdaq and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the Company that the minimum bid price per share for its common shares was below $1.00 for a period of 30 consecutive business days and that, as a result, the Company is currently not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company is not eligible for a grace period to regain compliance.

  • ACCESSWIRE23 days ago

    Intellipharmaceutics Reports Exclusive Supply Agreement for its Abuse-Deterrent Oxycodone ER Product Candidate and Four Generic Drug Products in the Philippines

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced it has entered into an exclusive licensing and distribution agreement for its abuse resistant Oxycodone ER product candidate and four generic drug products with a pharmaceutical distributor in the Philippines. ''Our supply agreement in the Philippines is another step forward in Intellipharmaceutics' goal to impact the global opioid market,'' commented Dr. Isa Odidi, CEO of Intellipharmaceutics.

  • ACCESSWIRE24 days ago

    Intellipharmaceutics Reports Exclusive Distribution Agreements in Malaysia and Vietnam

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced it has entered into two exclusive licensing and distribution agreements with pharmaceutical distributors in Malaysia and Vietnam. "We are extremely pleased to announce our entry into agreements for non-US generics in these markets," commented Dr. Isa Odidi, CEO of the Company. "Intellipharmaceutics has a strong portfolio of U.S. FDA approved generics and is committed to monetizing them by aggressively pursuing global partnerships.

  • ACCESSWIRElast month

    Intellipharmaceutics Announces Resignation of Chief Financial Officer

    TORONTO, ON / ACCESSWIRE / November 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the resignation of Andrew Patient, Chief Financial Officer, effective November 30, 2018 to pursue another opportunity. Mr. Patient has agreed to continue to offer his services to the Company through December 31, 2018 and is willing to continue thereafter on a consulting basis at the Company's discretion. Dr. Isa Odidi, Chairman, Chief Executive Officer and Co-Chief Scientist of the Company, commented "On behalf of the management team and the Board of Directors, I would like to thank Andrew for his contributions to Intellipharmaceutics, and to wish him every future success.

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Regains Compliance with Nasdaq Minimum Shareholders' Equity Listing Requirements

    TORONTO, ON / ACCESSWIRE / October 26, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from the Hearings Advisor from the Nasdaq Office of General Counsel notifying the Company that it had regained compliance with Nasdaq's stockholders' equity requirement. The letter also informed the Company that the Company will remain subject to a "Panel Monitor" under Nasdaq Listing Rule 5815(d)(4)(A) until October 22, 2019.

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Announces Closing of US $14.3 Million Underwritten Public Offering

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the closing of its previously announced underwritten public offering in the United States, resulting in the sale of 2,775,231 common shares, pre-funded warrants exercisable for 16,563,335 common shares, at an exercise price of US$0.01 per share (the "Pre-Funded Warrants"), and warrants exercisable for 20,000,000 common shares, at an exercise price of US$0.75 per share (the "Firm Warrants").

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Announces Third Quarter 2018 Results

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2018. "We made great progress with respect to our development programs in the third quarter, despite challenging financial circumstances," said Dr. Isa Odidi, CEO of Intellipharmaceutics. In October 2018, we entered into an Underwriting Agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), pursuant to which we agreed to issue and sell, in an underwritten public offering (the "October 2018 Offering"), 827,970 common shares and an aggregate of 16,563,335 pre-funded warrants ("Pre-Funded Warrants") exercisable into an aggregate of 16,563,335 common shares (the "Warrant Shares") together with common share purchase warrants to purchase up to an aggregate of 17,391,305 common shares ("Firm Warrants").

  • Benzinga2 months ago

    Don't Fixate On Market Woes, Just Make Your Trades

    Beyond my recent losses, October has actually been a strong month for me, although some in the chat are wondering how the recent market-wide selloff is affecting day traders. It was a fairly typical day for me, I was up, then down, then up again. Two of the top stocks to appear on my premarket scanner on Thursday, Spherix Inc. (NASDAQ: SPEX) and Compugen Ltd. (NASDAQ: CGEN), both collapsed on the opening bell.

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Announces Pricing of $13 Million Upsized Underwritten Public Offering

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of an aggregate of 17,391,305 units. Each unit is comprised of one common share (or common share equivalent) and one warrant to purchase one common share. The units are being offered at a public offering price of $0.75 per unit.

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Announces Completion of the Clinical Component of Category 2 and 3 Human Abuse Liability Studies for Oxycodone ER

    TORONTO, ON / ACCESSWIRE / October 10, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI; TSX : IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company ...

  • ACCESSWIRE2 months ago

    Intellipharmaceutics Regains Compliance with NASDAQ Minimum Bid Price Requirement; Also Receives Requested Extension from NASDAQ Panel

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listing Qualifications notifying the Company that it had regained compliance with Nasdaq's minimum bid price requirement. The letter noted that as of September 28, 2018, the Company evidenced a closing bid price of its common shares in excess of the $1.00 minimum requirement for at least ten consecutive business days.

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Announces One-for-10 Reverse Stock Split

    TORONTO, ONTARIO / ACCESSWIRE / September 13, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid-dosage drugs, announced today that it implemented a one-for-ten share consolidation (the "reverse split"). At a special meeting of the Company's shareholders held on August 15, 2018, the Company's shareholders granted the Company's Board of Directors discretionary authority to implement a consolidation of the issued and outstanding common shares of the Company on the basis of a consolidation ratio within a range from five (5) pre-consolidation common shares for one (1) post-consolidation common share to fifteen (15) pre-consolidation common shares for one (1) post-consolidation common share.

  • ACCESSWIRE3 months ago

    Intellipharmaceutics Closes US$0.5 Million Convertible Debenture Financing

    TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it issued in a private placement financing (the ''Financing'') an unsecured convertible debenture in the principal amount of US$0.5 million (the ''Debenture''), which will mature September 1, 2020. The Debenture bears interest at a rate of 10% per annum, payable monthly, is pre-payable at any time at the option of the Company, and is convertible at any time into common shares at a conversion price of US$0.30 per common share at the option of the holder. If the Debenture is fully converted into common shares of the Company, the shares would represent approximately 3.8% of the Company's currently issued common shares on a non-diluted basis.

  • ACCESSWIRE5 months ago

    Blog Exposure - Cambrex Announces Halo Pharma Acquisition

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want access to our free research report on Cambrex Corp. (NYSE: CBM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBM as the Company's latest news hit the wire. On July 23, 2018, the Company announced that it has inked a deal to acquire Halo Pharma, which is a leading dosage form Contract Development and Manufacturing Organization (CDMO), majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million in cash. Active-Investors.com is currently working on the research report for IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), which also belongs to the Healthcare sector as the Company Cambrex.

  • Associated Press5 months ago

    Intellipharmaceutics: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Toronto-based company said it had a loss of 7 cents. The extended-release drug developer posted revenue of $577,000 in the period. The company's shares closed at 47 cents. A year ...

  • ACCESSWIRE5 months ago

    Intellipharmaceutics Announces Second Quarter 2018 Results

    TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...

  • ACCESSWIRE6 months ago

    Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ

    TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listings Qualification staff (the "Staff") formally notifying the Company that its 180-day grace period for the $1.00 per share bid price requirement period has expiredand that therefore the Company is non-compliant with Nasdaq Listing Rule 5550(a)(2). While the Company understands has the opportunity to provide a submission to the Nasdaq Hearings Panel (the''Panel''), it does not intend to do so since the Company proactively addressed the bid price issue at the hearing held on May 17, 2018, and since Panel has already granted the Company a further extension within which to address the bid price issue.

  • ACCESSWIRE7 months ago

    Nasdaq Hearings Panel Grants Intellipharmaceutics' Request for Continued Listing

    TORONTO, ON / ACCESSWIRE / May 22, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received notice from the Nasdaq Hearings Panel granting its request for continued listing until September 28, 2018 while the Company works to regain compliance with Nasdaq's requirements. At a hearing held on May 17, 2018, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements.